Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...

Robert Kennedy Jr. indicated he would consider authorizing the government to seize patents of high-priced medicines to lower ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Behind the blinding white light of Monday's trillion–dollar AI wipeout that was a spot of unabashedly good AI news.

Prices in British shops fell a bit less sharply in January than in December and food costs rose at the fastest monthly pace ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Recent health news includes significant developments such as Akero Therapeutics' promising liver disease drug, potential ...

Anti-abortion groups aren’t lobbying against RFK Jr., U.S. reported first case of H5N9 bird flu strain, Sage Therapeutics ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...